Monoclonal antibodies for prophylactic and therapeutic use against viral infections

Both, Leonard; Banyard, Ashley C.; Dolleweerd, Craig J. van; Wright, Edward; K.‐C., Julian; Fooks, Anthony R.

doi:10.1016/j.pepo.2013.08.006

Cited by 27 publications

(33 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…113,114 Application of the monoclonal antibody principle to the plant biotechnology sector off ers a further promising direction for novel preparations where monoclonal antibody cocktails generated in plants enables ease of increased production and are economically advantageous. 115,116 Development of recombinant rabies vaccines has been proposed through the application of reverse genetics to generate rabies viruses with modifi ed properties. 108 Ideally, to generate more robust memory responses, vaccine preparations could involve liveattenuated virus to elicit a strong memory response, although use as either a pre-exposure or post-exposure option requires extensive development.…”

Section: Post-exposure Prophylaxismentioning

confidence: 99%

Current status of rabies and prospects for elimination

et al. 2014

View full text Add to dashboard Cite

Rabies is one of the most deadly infectious diseases, with a case-fatality rate approaching 100%. The disease is established on all continents apart from Antarctica; most cases are reported in Africa and Asia, with thousands of deaths recorded annually. However, the estimated annual figure of almost 60,000 human rabies fatalities is probably an underestimate. Almost all cases of human rabies result from bites from infected dogs. Therefore, the most cost-effective approach to elimination of the global burden of human rabies is to control canine rabies rather than expansion of the availability of human prophylaxis. Mass vaccination campaigns with parenteral vaccines, and advances in oral vaccines for wildlife, have allowed the elimination of rabies in terrestrial carnivores in several countries worldwide. The subsequent reduction in cases of human rabies in such regions advocates the multidisciplinary One Health approach to rabies control through the mass vaccination of dogs and control of canine populations.

show abstract

Section: Post-exposure Prophylaxismentioning

confidence: 99%

Current status of rabies and prospects for elimination

et al. 2014

View full text Add to dashboard Cite

show abstract

“…mAb therapies to viral infections, such as EBV (rituximab) or RSV (palivizumab), provide passive immunization and are licensed, whereas similar agents targeting influenza and other viruses are in preclinical development. 95 Neutralizing antibodies can bind and inactivate viruses, inhibit viral cell entry (blocking receptor binding or conformational changes), prevent the release of virions from the cell, or modulate immune effector functions. 96,97 Engineering and production strategies to produce antibody fragments, higher-affinity binding, and longer half-life are contributing to a lower overall cost for therapy, 95 although vaccines are still considered preferable in most cases.…”

Section: Vaccines and Mabsmentioning

confidence: 99%

Promising approaches for the treatment and prevention of viral respiratory illnesses

Papadopoulos

Megremis

Kitsioulis

et al. 2017

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Viral respiratory tract infections are the most common human ailments, leading to enormous health and economic burden. Hundreds of viral species and subtypes have been associated with these conditions, with influenza viruses, respiratory syncytial virus, and rhinoviruses being the most frequent and with the highest burden. When considering prevention or treatment of viral respiratory tract infections, potential targets include the causative pathogens themselves but also the immune response, disease transmission, or even just the symptoms. Strategies targeting all these aspects are developing concurrently, and several novel and promising approaches are emerging. In this perspective we overview the entire range of options and highlight some of the most promising approaches, including new antiviral agents, symptomatic or immunomodulatory drugs, the re-emergence of natural remedies, and vaccines and public health policies toward prevention. Wide-scale prevention through immunization appears to be within reach for respiratory syncytial virus and promising for influenza virus, whereas additional effort is needed in regard to rhinovirus, as well as other respiratory tract viruses.

show abstract

“…This step is challenging since the neutralization capacity of antibodies often depends on the antibody valency as observed for HSV, varicella-zoster virus, HIV, and rabies [27,28]. In these cases, bivalent antibodies (IgG) or antibody fragments (F(ab) 2 ) neutralized the virus with an exceptional efficiency, while monovalent Fab or scFv fragments did not or only when used at very high concentrations (e.g., 300 times higher than IgG).…”

Section: Preliminary Notes Prior To Antibody Fragment Production and mentioning

confidence: 99%

Detailed Protocols for the Selection of Antiviral Human Antibodies from Combinatorial Immune Phage Display Libraries

Diebolder¹,

Krawczyk²

2018

Antibody Engineering

View full text Add to dashboard Cite

Broadly, neutralizing antiviral antibodies holds great promise for improving treatment opportunities for patients suffering from viral infections (e.g., human immunodeficiency virus [HIV], hepatitis B virus [HBV], cytomegalovirus [CMV], Rabies, Ebola, Zika) leading to serious health disorders or even to death without effective antiviral treatment. The potential of antibodies in host protection against lethal viral infections has been demonstrated in numerous animal models and is best exemplified by the protection conferred to neonates by maternal antibodies. Over the past few decades, virus-neutralizing human monoclonal antibodies (nAbs) have been isolated from humans successfully cured of disease using a wide range of recently developed antibody isolation technologies. In this chapter, we present an approach for isolating recombinant human nAbs from combinatorial gene libraries being cloned from individuals who have recovered from viral infections. The presented protocols describe the selection and screening of antiviral single-chain antibody fragments (scFvs) from phage display immune libraries. This technology represents a well-established, high-throughput approach allowing fast selection of broadly neutralizing, antiviral antibodies. The protocols for generating and selecting antigen-specific scFvs can be applied for the selection of scFvs against any target.

show abstract

Monoclonal antibodies for prophylactic and therapeutic use against viral infections

Cited by 27 publications

References 100 publications

Current status of rabies and prospects for elimination

Current status of rabies and prospects for elimination

Promising approaches for the treatment and prevention of viral respiratory illnesses

Detailed Protocols for the Selection of Antiviral Human Antibodies from Combinatorial Immune Phage Display Libraries

Contact Info

Product

Resources

About